Journal article icon

Journal article

Anti-tumor necrosis factor therapies.

Abstract:

Recently published studies confirm that the long-term use of biologicals targeting tumor necrosis factor-alpha (TNF-alpha) in therapy for rheumatoid arthritis (RA) gives rise to sustained improvement in symptoms and signs of disease provided the anti-TNF agent is efficacious and of low immunogenicity. The current regimens for infliximab 3 or 10 mg/kg infusion in combination with weekly oral methotrexate, or of etanercept 25 mg subcutaneously twice per week, appear to fulfill these criteria. D...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, NDORMS
Journal:
Current opinion in rheumatology
Volume:
13
Issue:
3
Pages:
164-169
Publication date:
2001-05-05
DOI:
EISSN:
1531-6963
ISSN:
1040-8711
URN:
uuid:67ef9db6-5028-4698-b805-621992d9ee51
Source identifiers:
227373
Local pid:
pubs:227373

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP